WO2006083608A1 - Process for producing polypeptide mixtures using hydrogenolysis - Google Patents

Process for producing polypeptide mixtures using hydrogenolysis Download PDF

Info

Publication number
WO2006083608A1
WO2006083608A1 PCT/US2006/002351 US2006002351W WO2006083608A1 WO 2006083608 A1 WO2006083608 A1 WO 2006083608A1 US 2006002351 W US2006002351 W US 2006002351W WO 2006083608 A1 WO2006083608 A1 WO 2006083608A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
mixture
daltons
molecular weight
peak molecular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/002351
Other languages
French (fr)
Inventor
Ben-Zion Dolitzky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Original Assignee
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2007009296A priority Critical patent/MX2007009296A/en
Priority to EP06719275A priority patent/EP1838326A4/en
Priority to NZ556156A priority patent/NZ556156A/en
Priority to CA002594022A priority patent/CA2594022A1/en
Priority to BRPI0606301-2A priority patent/BRPI0606301A2/en
Application filed by Teva Pharmaceutical Industries Ltd, Teva Pharmaceuticals USA Inc filed Critical Teva Pharmaceutical Industries Ltd
Priority to AU2006211510A priority patent/AU2006211510B8/en
Priority to JP2007553163A priority patent/JP2008528589A/en
Publication of WO2006083608A1 publication Critical patent/WO2006083608A1/en
Priority to IL183610A priority patent/IL183610A0/en
Priority to IS8657A priority patent/IS8657A/en
Anticipated expiration legal-status Critical
Priority to NO20074374A priority patent/NO20074374L/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/12General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by hydrolysis, i.e. solvolysis in general
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • Glatirainer acetate is a mixture of polypeptides which has been approved for the treatment of multiple sclerosis .
  • COPAXONE® the brand name for a pharmaceutical composition which contains glatiramer acetate (GA) as the active ingredient, contains the acetate salts of synthetic polypeptides, containing four naturally occurring amino acids : L-glutamic acid, L-alanine, L-tyrosine, and L-lysine with an average molar fraction of 0.141, 0.427 , 0.095, and 0.338 , respectively.
  • the average molecular weight of glatiramer acetate is 4, 700 - 11 , 000 daltons .
  • Chemically, glatiramer acetate is designated L-glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) . Its structural formula is :
  • polypeptides of this type were prepared from the N- carboxyanhydrides of tyrosine, alanine, ⁇ -benzyl glutamate and ⁇ -N-trifluoro-acetyllysine .
  • the polymerization was carried out at ambient temperature in anhydrous dioxane with diethylamine as initiator .
  • the deblocking of the ⁇ -carboxyl group of the glutamic acid was affected by hydrogen bromide (HBr) in glacial acetic acid and is followed by the removal of the trifluoroacetyl groups from the lysine residues by IM piperidine (U. S . Patent No . 3 , 849 , 550 , issued November 19, 1974 to Teitelbaum, et al . ) .
  • the subj ect invention provides for a process for making a mixture of acetate salts of polypeptides , each of which consisting of glutamic acid, alanine, tyrosine and lysine, wherein the mixture has a desired peak molecular weight, comprising : a) polymerizing N-carboxyanhydrides of tyrosine, alanine, ⁇ -benzyl glutamate and trifluoroacetyllysine with an initiator in an amount of 0.01% to 20% by weight for a suitable period of time and at a suitable temperature to form a mixture of protected polypeptides , which mixture of polypeptides in unprotected form having a first peak molecular weight ; b) removing the benzyl protecting group from the mixture of protected polypeptides by contacting the polypeptides with a hydrogenolysis catalyst and hydrogen to produce a mixture of trifluoroacetyl protected polypeptides , which mixture of polypeptides in
  • the subject invention also provides for a process for making a mixture of trifluoroacetyl protected polypeptides , each of which consisting of glutamic acid, alanine, tyrosine and trifluoroacetyllysine, wherein the mixture of polypeptides in unprotected form has a first peak molecular weight, comprising: a .
  • the subj ect invention provides for a process for making a mixture of acetate salts of polypeptides , each of which consisting of glutamic acid, alanine, tyrosine and lysine, wherein the mixture has a desired peak molecular weight, comprising : a) polymerizing N-carboxyanhydrides of tyrosine, alanine, ⁇ -benzyl glutamate and trifluoroacetyllysine with an initiator in an amount of 0.01% to 20% by weight for a suitable period of time and at a suitable temperature to form a mixture of protected polypeptides , which mixture of polypeptides in unprotected form having a first peak molecular weight ; b) removing the benzyl protecting group from the mixture of protected polypeptides by contacting the polypeptides with a hydrogenolysis catalyst and hydrogen to produce .
  • the first peak molecular weight may be 2 , 000 daltons to 40 , 000 daltons, or 2 , 000 daltons to 20 , 000 daltons or 4, 000 daltons to 8 , 600 daltons or 4 , 000 daltons to 8 , 000 daltons or 6 , 250 daltons to 8 , 400 daltons or 2 , 000 daltons to 13 , 000 daltons or 4 , 700 daltons to 13 , 000 daltons or 10 , 000 daltons to 25 , 000 daltons or 15 , 000 daltons to 25 , 000 daltons or 18 , 000 daltons to 25 , 000 daltons or 20 , 000 daltons to 25 , 000 ddaallttoonnss oorr 4 , 700 daltons to 11 , 000 daltons or 7 , 000 daltons or 13 , 000 daltons to 18, 000 daltons or 15 , 000 daltons or 12 , 500 daltons .
  • the desired peak molecular weight may be any suitable peak molecular weight.
  • the hydrogenolysis catalyst may be Palladium/carbon, Raney Nickel, Pt, Pt/C, Pt ⁇ 2 , Pd(OH) 2 , Rh/C, or RhCl (PPh 3 ) 3 •
  • the hydrogenolysis catalyst may be Palladium/carbon.
  • the weight ratio of protected polypeptide to palladium/carbon catalyst may be 10 : 1.
  • the step of contacting the polypeptides with the hydrogenolysis catalyst may be performed in a solvent selected from the group consisting of methanol , ethanol or isopropanol .
  • the solvent may be methanol .
  • the initiator may be a primary amine, a dialkyl amine or sodium methoxide .
  • the initiator may be diethylamine .
  • the amount of initiator may be 0.05% to 19% by weight or 0.1% to 17% by weight or 0.5% to 15% by weight or 1% to 10% by weight or 2% to 5% by weight or 2% by weight or 5% by weight .
  • the organic base in step c) may be an aqueous organic base .
  • the aqueous organic base may be a primary, secondary or tertiary amine or methanolic ammonia .
  • the aqueous organic base may be piperidine .
  • the subject invention also provides for a mixture of acetate salts of polypeptides made by the previous processes .
  • the subject invention further provides for a pharmaceutical composition comprising the previous mixture and a pharmaceutically acceptable carrier .
  • the subject invention still further provides for a process for preparing a pharmaceutical composition comprising mixing the previous mixture with a pharmaceutically acceptable carrier .
  • the subj ect invention further provides for a process for preparing a pharmaceutical composition containing an aqueous mixture of acetate salts of polypeptides each of which consisting of glutamic acid, alanine, tyrosine and lysine , wherein the mixture has a desired peak molecular weight , the improvement comprising making the mixture of acetate salts of polypeptides by any one of the previous processes .
  • the subj ect invention provides for a process for making a mixture of trifluoroacetyl protected polypeptides , each of which consisting of glutamic acid, alanine, tyrosine and trifluoroacetyllysine, wherein the mixture of polypeptides in unprotected form has a first peak molecular weight, comprising : a ) polymerizing N-carboxyanhydrides of tyrosine, alanine, ⁇ -benzyl glutamate and trifluoroacetyllysine with an initiator in an amount of 0.01% to 20% by weight for a suitable period of time and at a suitable temperature to form a mixture of protected polypeptides , which mixture of polypeptides in unprotected form having a first peak molecular weight ; and b) removing the benzyl protecting group from the mixture of protected polypeptides by contacting the polypeptides with a hydrogenolysis catalyst and hydrogen, to obtain the mixture of tri
  • the hydrogenolysis catalyst may be Palladium/carbon.
  • the weight ratio of protected polypeptide to palladium/carbon catalyst may be 10 : 1.
  • the step of contacting the polypeptides with a hydrogenolysis catalyst may be performed in a solvent selected from the group consisting of methanol, ethanol or isopropanol .
  • the solvent may be methanol .
  • the initiator may be a primary amine, a dialkyl amine or sodium methoxide .
  • the initiator may be diethylamine .
  • the amount of initiator may be 0.05% to 19% by weight or 0.1% to 17% by weight or 0.5% to 15% by weight or 1% to 10% by weight or 2% to 5% by weight or 2% by weight or 5% by weight .
  • the first peak molecular weight may be 2 , 000 daltons to 40 , 000 daltons or 2 , 000 daltons to 20 , 000 daltons or 4, 000 daltons to 8 , 600 daltons or 4 , 000 daltons to 8 , 000 daltons or 6 , 250 daltons to 8, 400 daltons or 2 , 000 daltons to 13 , 000 daltons or 4700 to 13 , 000 daltons or 10 , 000 daltons to 25 , 000 daltons or 15 , 000 daltons to 25 , 000 daltons or 18 , 000 daltons to 25 , 000 daltons or 20 , 000 daltons to 25 , 000 daltons or 4 , 700 daltons to 11 , 000 daltons or 7 , 000 daltons or 13 , 000 daltons to 18 , 000 daltons or 15 , 000 daltons or 12 , 500 daltons .
  • the subject invention also provides for a mixture of trifluoroacetyl protected polypeptides each of which consisting of glutamic acid, alanine, tyrosine and trifluoroacetyllysine produced by any one of the immediately preceding processes .
  • the subject invention also provides for a process of making a mixture of acetate salts of polypeptides, each of which consisting of glutamic acid, alanine, tyrosine and lysine, wherein the mixture has a desired peak molecular weight, comprising : a) treating the previous mixture with an organic base solution, b) removing the free trifluoroacetyl groups and low molecular weight impurities by ultrafiltration to obtain a mixture of polypeptides each of which consisting of glutamic acid, alanine, tyrosine and lysine, and c) contacting the mixture of polypeptides with an aqueous solution of acetic acid to form the mixture of acetate salts of polypeptides, each of which consisting of glutamic acid, alanine, tyrosine and lysine having the desired peak molecular weight .
  • the organic base may be an aqueous organic base .
  • the aqueous organic base may be a primary, secondary or tertiary amine or methanolic ammonia .
  • the aqueous organic base may be piperidine.
  • reaction mixture was then added to 5L deionized water.
  • the solid reaction product was filtered, washed and dried at 6O 0 C under vacuum. 65.6g of solid white-off-white powder was produced.
  • the molecular weight of the product of Example 3 was determined using a Superose 12 HR Gel Permeation HPLC column, equipped with an UV detector . Phosphate buffer, pH 1.5 was used as the mobile phase .
  • the total retention time of the column was determined using 200 ⁇ l of acetone diluted with 1 ml of water .
  • the column was calibrated using TV molecular weight markers using Millennium calculations which were described in US Patent 6 , 514 , 938 , issued February 4, 2003 (Gad, et al . ) (see specifically Example 2 ) hereby incorporated by reference.
  • a sample solution was prepared using 10 mg of the polypeptide from Example 3 added to an arginine internal control solution .
  • the sample solution was hydrolyzed using concentrated HCl containing 1% (w/v) phenol , under a N2 atmosphere at 110 0 C for 24 hours .
  • Amino acid control solutions each containing one of glutamate, alanine, tyrosine, and lysine HCl were prepared and hydrolyzed.
  • the sample solution and the controls were derivatized with ortho-phthaldialdehyde .
  • the samples and controls were analyzed using a Merck LiChrosorb RP18 7 ⁇ m column equipped with an UV detector .
  • the mobile phase was phosphate buffer pH 2.5/ acetonitirile gradient .
  • the molar fractions of the amino acids in the polypeptide sample were determined based on peak area .
  • the product of any one of Examples 1-3 is contacted with an aqueous solution of acetic acid to form the polypeptide acetate salt .
  • the inventors of the disclosed invention found that hydrogenolysis is effective in removing the benzyl groups from glutamate residues of the protected polypeptides .
  • the inventors of the instant invention found that the use of hydrogenolysis using a palladium/carbon catalyst is effective in removing the benzyl groups from glutamate residues to form a trifluoroacetyl polypeptide, which is protected by the trifluoroacetyl groups on the lysine residues .
  • Catalyst for example palladium/carbon, can be recovered and reused thereby eliminating waste .
  • the trifluoroacetyl groups were subsequently removed from the lysine residues by piperidine .
  • hydrogenolysis catalysts may also be used to remove the benzyl groups from the glutamate residues .
  • Such known hydrogenolysis catalysts are Raney Nickel , Pt , Pt/C, PtO 2 , Pd (OH) 2 , Bh/C, RhCl (PPh 3 J 3 , and other transition metal catalysts .
  • the hydrogenolysis reaction can be performed at a temperature between 20 0 C and 100 0 C and a pressure between 1 atm and 100 atm.
  • HBr/acetic acid When HBr/acetic acid is used, it serves the dual function of both removing the benzyl groups from the glutamate residues and cleaving the polypeptide to achieve a desired average molecular weight of the mixture . Hydrogenolysis , however, does not cleave the polypeptide . Therefore, inventors of the disclosed process further modified the production process to achieve the desired peak molecular weight by using specific amounts of the initiator of the polymerization reaction .
  • Initiators that can be used are n-hexylamine and other primary amines , diethylamine and other other dialkyl amines , or sodium methoxide or any combination of initiators .
  • U. S . Patent No . 5 , 800 , 808 , issued September 1, 1998 discloses the use of 0.1-0.2% diethylamine as an initiator in a process conducted at room temperature for 24 hours that also uses HBr to achieve polypeptides with a molecular weight in the range of 5000-9000 daltons .
  • determination of the peak molecular weight of the mixture of polypeptides can be conducted after polymerization of the polypeptide but before removal of either the benzyl protecting group or the trifluoroacetyl protecting group .
  • the peak molecular weight of the mixture of polypeptides may be determined after removal of the benzyl protecting but before removal of the trifluoroacetyl protecting group .
  • Still another alternative in any embodiment of the subject invention is to determine the peak molecular weight of the mixture of polypeptides after removal of both protecting groups from the polypeptide . Adjustment of the peak molecular weight of the mixture of polypeptides can similarly be performed at the mentioned steps of the process by known techniques such as chromatographic fractionation, filtration, ultrafiltration dialysis , enzymatic hydrolysis or sedimentation.
  • the subject invention provides a process for making a mixture of acetate salts of polypeptides each of which consisting of glutamic acid, alanine, tyrosine and lysine which provides reduced production of aqueous waste and improved control of the peak molecular weight of the mixture of acetate salts of polypeptides .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Polyamides (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to an improved process for making a mixture of acetate salts of polypeptides, each of which consisting of glutamic acid, alanine, tyrosine and lysine, for use in the treatment of multiple sclerosis.

Description

PROCESS FOR PRODUCING POLYPEPTIDE MIXTURES USING HYDROGENOLYSIS
Throughout this application various publications are referenced by their full citations . The disclosures of these publications in their entireties are hereby- incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains .
BACKGROUND OF THE INVENTION
Glatirainer acetate (GA) is a mixture of polypeptides which has been approved for the treatment of multiple sclerosis .
COPAXONE®, the brand name for a pharmaceutical composition which contains glatiramer acetate (GA) as the active ingredient, contains the acetate salts of synthetic polypeptides, containing four naturally occurring amino acids : L-glutamic acid, L-alanine, L-tyrosine, and L-lysine with an average molar fraction of 0.141, 0.427 , 0.095, and 0.338 , respectively. The average molecular weight of glatiramer acetate is 4, 700 - 11 , 000 daltons . Chemically, glatiramer acetate is designated L-glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) . Its structural formula is :
(GIu, Ala, Lys, Tyr) χ»χCH3COOH (C5H9NO4•C3H7NO2•C6H14N2O2 •C9HuNO3) x• XC2H4O2
CAS - 147245-92-9
( "Copaxone" , Physician' s Desk Reference, (2000 ) , Medical Economics Co . , Inc . , (Montvale, NJ) , 3115. )
Processes of manufacturing polypeptides of this type, including glatiramer acetate, are described in U. S . Patent No . 3 , 849 , 550 , issued November 19 , 1974 to Teitelbaum, et al . , U. S . Patent No. 5, 800 , 808 , issued September 1, 1998 to Konfino, et al . , and PCT International Publication No. WO 00/05250 , published February 3 , 2000 (Aharoni, et al . ) which are hereby incorporated by reference . For example, polypeptides of this type were prepared from the N- carboxyanhydrides of tyrosine, alanine, γ-benzyl glutamate and ε-N-trifluoro-acetyllysine . The polymerization was carried out at ambient temperature in anhydrous dioxane with diethylamine as initiator . The deblocking of the γ-carboxyl group of the glutamic acid was affected by hydrogen bromide (HBr) in glacial acetic acid and is followed by the removal of the trifluoroacetyl groups from the lysine residues by IM piperidine (U. S . Patent No . 3 , 849 , 550 , issued November 19, 1974 to Teitelbaum, et al . ) .
The deprotection of the γ-carboxyl group of the glutamic acid requires the use of large amounts of HBr/acetic acid. As a result, a large volume of acidic waste is produced. The disposal of this acidic waste is difficult and costly. Alternate methods of production of such polypeptides are desirable in order to eliminate the problems of acidic waste products .
SUMMARY OF THE INVENTION
The subj ect invention provides for a process for making a mixture of acetate salts of polypeptides , each of which consisting of glutamic acid, alanine, tyrosine and lysine, wherein the mixture has a desired peak molecular weight, comprising : a) polymerizing N-carboxyanhydrides of tyrosine, alanine, γ-benzyl glutamate and trifluoroacetyllysine with an initiator in an amount of 0.01% to 20% by weight for a suitable period of time and at a suitable temperature to form a mixture of protected polypeptides , which mixture of polypeptides in unprotected form having a first peak molecular weight ; b) removing the benzyl protecting group from the mixture of protected polypeptides by contacting the polypeptides with a hydrogenolysis catalyst and hydrogen to produce a mixture of trifluoroacetyl protected polypeptides , which mixture of polypeptides in unprotected form having the first peak molecular weight; c ) removing the trifluoroacetyl protecting group from the trifluoroacetyl protected polypeptides by contacting the polypeptides with an organic base solution to form a mixture of polypeptides , which mixtures of polypeptides in unprotected form having the first peak molecular weight ; d) removing the free trifluoroacetyl groups and low molecular weight impurities by ultrafiltration to obtain the mixture of polypeptides each of which consisting of glutamic acid, alanine, tyrosine and lysine ; and e ) contacting the mixture of polypeptides each of which consisting of glutamic acid, alanine, tyrosine and lysine with an aqueous solution of acetic acid to form the mixture of acetate salts of polypeptides each of which consisting of glutamic acid, alanine, tyrosine and lysine and having the desired peak molecular weight .
The subject invention also provides for a process for making a mixture of trifluoroacetyl protected polypeptides , each of which consisting of glutamic acid, alanine, tyrosine and trifluoroacetyllysine, wherein the mixture of polypeptides in unprotected form has a first peak molecular weight, comprising: a . polymerizing N-carboxyanhydrides of tyrosine, alanine, γ-benzyl glutamate and trifluoroacetyllysine with an initiator in an amount of 0.01% to 20% by weight for a suitable period of time and at a suitable temperature to form a mixture of protected polypeptides , which mixture of polypeptides in unprotected form having a first peak molecular weight; and b. removing the benzyl protecting group from the mixture of protected polypeptides by contacting the polypeptides with a hydrogenolysis catalyst and hydrogen, to obtain the mixture of trifluoroacetyl protected polypeptides each of which consisting of glutamic acid, alanine, tyrosine and trifluoroacetyllysine and which mixture of polypeptides in unprotected form having the first peak molecular weight .
DETAIIiED DESCRIPTION OF THE INVENTION
The subj ect invention provides for a process for making a mixture of acetate salts of polypeptides , each of which consisting of glutamic acid, alanine, tyrosine and lysine, wherein the mixture has a desired peak molecular weight, comprising : a) polymerizing N-carboxyanhydrides of tyrosine, alanine, γ-benzyl glutamate and trifluoroacetyllysine with an initiator in an amount of 0.01% to 20% by weight for a suitable period of time and at a suitable temperature to form a mixture of protected polypeptides , which mixture of polypeptides in unprotected form having a first peak molecular weight ; b) removing the benzyl protecting group from the mixture of protected polypeptides by contacting the polypeptides with a hydrogenolysis catalyst and hydrogen to produce . a mixture of trifluoroacetyl protected polypeptides , which mixture of polypeptides in unprotected form having the first peak molecular weight ; c ) removing the trifluoroacetyl protecting group from the trifluoroacetyl protected polypeptides by contacting the polypeptides with an organic base solution to form a mixture of polypeptides , which mixtures of polypeptides in unprotected form having the first peak molecular weight; d) removing the free trifluoroacetyl groups and low molecular weight impurities by ultrafiltration to obtain the mixture of polypeptides each of which consisting of glutamic acid, alanine, tyrosine and lysine ; and e ) contacting the mixture of polypeptides each of which consisting of glutamic acid, alanine, tyrosine and lysine with an aqueous solution of acetic acid to form the mixture of acetate salts of polypeptides each of which consisting of glutamic acid, alanine, tyrosine and lysine and having the desired peak molecular weight .
In an embodiment, the first peak molecular weight may be 2 , 000 daltons to 40 , 000 daltons, or 2 , 000 daltons to 20 , 000 daltons or 4, 000 daltons to 8 , 600 daltons or 4 , 000 daltons to 8 , 000 daltons or 6 , 250 daltons to 8 , 400 daltons or 2 , 000 daltons to 13 , 000 daltons or 4 , 700 daltons to 13 , 000 daltons or 10 , 000 daltons to 25 , 000 daltons or 15 , 000 daltons to 25 , 000 daltons or 18 , 000 daltons to 25 , 000 daltons or 20 , 000 daltons to 25 , 000 ddaallttoonnss oorr 4 , 700 daltons to 11 , 000 daltons or 7 , 000 daltons or 13 , 000 daltons to 18, 000 daltons or 15 , 000 daltons or 12 , 500 daltons .
In an embodiment, the desired peak molecular weight may be
2 , 000 daltons to 40 , 000 daltons or 2 , 000 daltons to 20 , 000 daltons or 4 , 000 daltons to 8 , 600 daltons or 4 , 000 daltons to 8 , 000 daltons or 6 , 250 daltons to 8 , 400 daltons or 2 , 000 daltons to 13 , 000 daltons or 4 , 700 daltons to 13 , 000 daltons or 10 , 000 daltons to 25 , 000 daltons or 15 , 000 daltons to 25 , 000 daltons or 18 , 000 daltons to 25 , 000 daltons or 20 , 000 daltons to 25, 000 daltons or 4 , 700 ddaallttoonnss ttoo 1 111 ,, 0 00000 ddaallttoonnss oorr 7 , 000 daltons or 13 , 000 daltons to 18 , 000 daltons or 15 , 000 daltons or 12 , 500 daltons .
In an embodiment, the hydrogenolysis catalyst may be Palladium/carbon, Raney Nickel, Pt, Pt/C, Ptθ2, Pd(OH) 2, Rh/C, or RhCl (PPh3) 3 •
In another embodiment, the hydrogenolysis catalyst may be Palladium/carbon.
In yet another embodiment, the weight ratio of protected polypeptide to palladium/carbon catalyst may be 10 : 1. In an embodiment, the step of contacting the polypeptides with the hydrogenolysis catalyst may be performed in a solvent selected from the group consisting of methanol , ethanol or isopropanol .
In another embodiment, the solvent may be methanol .
In an embodiment, the initiator may be a primary amine, a dialkyl amine or sodium methoxide .
In another embodiment, the initiator may be diethylamine .
In yet another embodiment, the amount of initiator may be 0.05% to 19% by weight or 0.1% to 17% by weight or 0.5% to 15% by weight or 1% to 10% by weight or 2% to 5% by weight or 2% by weight or 5% by weight .
In an embodiment, the organic base in step c) may be an aqueous organic base .
In another embodiment, the aqueous organic base may be a primary, secondary or tertiary amine or methanolic ammonia .
In yet another embodiment, the aqueous organic base may be piperidine .
The subject invention also provides for a mixture of acetate salts of polypeptides made by the previous processes .
The subject invention further provides for a pharmaceutical composition comprising the previous mixture and a pharmaceutically acceptable carrier .
The subject invention still further provides for a process for preparing a pharmaceutical composition comprising mixing the previous mixture with a pharmaceutically acceptable carrier .
The subj ect invention further provides for a process for preparing a pharmaceutical composition containing an aqueous mixture of acetate salts of polypeptides each of which consisting of glutamic acid, alanine, tyrosine and lysine , wherein the mixture has a desired peak molecular weight , the improvement comprising making the mixture of acetate salts of polypeptides by any one of the previous processes .
The subj ect invention provides for a process for making a mixture of trifluoroacetyl protected polypeptides , each of which consisting of glutamic acid, alanine, tyrosine and trifluoroacetyllysine, wherein the mixture of polypeptides in unprotected form has a first peak molecular weight, comprising : a ) polymerizing N-carboxyanhydrides of tyrosine, alanine, γ-benzyl glutamate and trifluoroacetyllysine with an initiator in an amount of 0.01% to 20% by weight for a suitable period of time and at a suitable temperature to form a mixture of protected polypeptides , which mixture of polypeptides in unprotected form having a first peak molecular weight ; and b) removing the benzyl protecting group from the mixture of protected polypeptides by contacting the polypeptides with a hydrogenolysis catalyst and hydrogen, to obtain the mixture of trifluoroacetyl protected polypeptides each of which consisting of glutamic acid, alanine, tyrosine and trifluoroacetyllysine and which mixture of polypeptides in unprotected form having the first peak molecular weight . In an embodiment, the hydrogenolysis catalyst may be Palladium/carbon, Raney Nickel , Pt, Pt/C, PtO2, Pd (OH) 2, Rh/C, or RhCl (PPh3J 3.
In another embodiment, the hydrogenolysis catalyst may be Palladium/carbon.
In yet another embodiment, the weight ratio of protected polypeptide to palladium/carbon catalyst may be 10 : 1.
In an embodiment, the step of contacting the polypeptides with a hydrogenolysis catalyst may be performed in a solvent selected from the group consisting of methanol, ethanol or isopropanol .
In another embodiment, the solvent may be methanol .
In yet another embodiment, the initiator may be a primary amine, a dialkyl amine or sodium methoxide .
In an embodiment, the initiator may be diethylamine .
In another embodiment, the amount of initiator may be 0.05% to 19% by weight or 0.1% to 17% by weight or 0.5% to 15% by weight or 1% to 10% by weight or 2% to 5% by weight or 2% by weight or 5% by weight .
In an embodiment, the first peak molecular weight may be 2 , 000 daltons to 40 , 000 daltons or 2 , 000 daltons to 20 , 000 daltons or 4, 000 daltons to 8 , 600 daltons or 4 , 000 daltons to 8 , 000 daltons or 6 , 250 daltons to 8, 400 daltons or 2 , 000 daltons to 13 , 000 daltons or 4700 to 13 , 000 daltons or 10 , 000 daltons to 25 , 000 daltons or 15 , 000 daltons to 25 , 000 daltons or 18 , 000 daltons to 25 , 000 daltons or 20 , 000 daltons to 25 , 000 daltons or 4 , 700 daltons to 11 , 000 daltons or 7 , 000 daltons or 13 , 000 daltons to 18 , 000 daltons or 15 , 000 daltons or 12 , 500 daltons . The subject invention also provides for a mixture of trifluoroacetyl protected polypeptides each of which consisting of glutamic acid, alanine, tyrosine and trifluoroacetyllysine produced by any one of the immediately preceding processes .
The subject invention also provides for a process of making a mixture of acetate salts of polypeptides, each of which consisting of glutamic acid, alanine, tyrosine and lysine, wherein the mixture has a desired peak molecular weight, comprising : a) treating the previous mixture with an organic base solution, b) removing the free trifluoroacetyl groups and low molecular weight impurities by ultrafiltration to obtain a mixture of polypeptides each of which consisting of glutamic acid, alanine, tyrosine and lysine, and c) contacting the mixture of polypeptides with an aqueous solution of acetic acid to form the mixture of acetate salts of polypeptides, each of which consisting of glutamic acid, alanine, tyrosine and lysine having the desired peak molecular weight .
In an embodiment of the previous process, the organic base may be an aqueous organic base .
In another embodiment of the previous process, the aqueous organic base may be a primary, secondary or tertiary amine or methanolic ammonia .
In yet another embodiment of the previous process, the aqueous organic base may be piperidine.
EXPERIMENTAL DETAILS EXAMPLE 1
Synthesis of Poly[5-benzyl-1-GIu, Nβ-TFA-L-Lys , L-AIa, L- Tyr] 7.43 g of L-tyrosine N-carboxyanhydride were added to 260 ml of dioxane and the mixture was heated to 600C for 20 minutes and was then filtered. 34.61 g of N6-trifluoroacetyl-L- Lysine N-carboxyanhydride were added to 630 ml of dioxane and the solution was stirred at 20-250C for 15 minutes and was then filtered. 21.25 g of L-alanine N-carboxyanhydride were added to 395 ml of dioxane and the solution was stirred at 20-250C for 15 minutes and was then filtered. 14.83 g of 5-benzyl L-glutamate N-carboxyanhydride were added to 260 ml of dioxane and the solution was stirred at 20-250C for 10 minutes and was then filtered.
The solutions were combined in a 2L Erlenmeyer flask equipped with a mechanical stirrer. The solutions were stirred together for 5 minutes . 3.9 g of diethylamine was then added to the reaction mixture . The mixture was stirred for 24 hours at 23-270C .
The reaction mixture was then added to 5L deionized water. The solid reaction product was filtered, washed and dried at 6O0C under vacuum. 65.6g of solid white-off-white powder was produced.
EXAMPLE 2
Deprotection (Hydrogenolysis) of Poly [5-benzyl-L-GIu, N6- TFA-L-Lys , L-AIa, L-Tyr] to form PoIy[L-GIu, N6-TFA-L-Lys, L-AIa, L-Tyr]
18 g of the solid product synthesized as described in Example 1 were suspended in 540 ml of methanol . 1.8 g of wet palladium on charcoal (10% Pd on charcoal type 87L Powder, Johnson Matthey - Precious Metals Division) was added. Hydrogenolysis was achieved by bubbling H2 at 2 Atm. for 7 hours through the mixture. The mixture was filtered. The reaction mixture was concentrated to 270 ml and was added to 600 ml of water. The mixture was stirred for one hour and the mixture was filtered and dried to yield 14 g of white- off-white powder.
EXAMPLE 3
Removal of the Trifluoroacetyl Group to form PoIy [L-GIu, L- Lys , L-AIa, L-Tyr] 9 g of the product synthesized in Example 2 were added to 540 ml of water. 60 ml of piperidine were added to the mixture, and the mixture was stirred at room temperature for 24 hours . The mixture was filtered and a clear filtrate with a yellowish tint was attained. Ultrafiltration was performed using a 5 kilodalton membrane, to remove all of the low- molecular weight impurities . After 6 cycles of ultrafiltration, the solution was acidified with acetic acid until a pH of 4.0 was achieved. Water was added and the solution was ultrafiltrated until a pH of 5.5 was attained. The solution was concentrated and lyophilized for 60 hours . 4.7 g of a white, lyophilized cake of PoIy[L-GIu, L-Lys, L- AIa, L-Tyr] was attained.
EXAMPLE 4
Molecular Weight Analysis
The molecular weight of the product of Example 3 was determined using a Superose 12 HR Gel Permeation HPLC column, equipped with an UV detector . Phosphate buffer, pH 1.5 was used as the mobile phase .
The total retention time of the column was determined using 200 μl of acetone diluted with 1 ml of water . The column was calibrated using TV molecular weight markers using Millennium calculations which were described in US Patent 6 , 514 , 938 , issued February 4, 2003 (Gad, et al . ) (see specifically Example 2 ) hereby incorporated by reference.
After calibration, a solution of 5 mg/ml of the product of Example 3 was prepared. The peak maximum retention time was measured, and the peak molecular weight was determined to be 12 , 700 daltons .
EXAMPLE 5
Hydrolysis and Determination of Amino Acid Content A sample solution was prepared using 10 mg of the polypeptide from Example 3 added to an arginine internal control solution . The sample solution was hydrolyzed using concentrated HCl containing 1% (w/v) phenol , under a N2 atmosphere at 1100C for 24 hours . Amino acid control solutions , each containing one of glutamate, alanine, tyrosine, and lysine HCl were prepared and hydrolyzed. The sample solution and the controls were derivatized with ortho-phthaldialdehyde .
The samples and controls were analyzed using a Merck LiChrosorb RP18 7 μm column equipped with an UV detector . The mobile phase was phosphate buffer pH 2.5/ acetonitirile gradient . The molar fractions of the amino acids in the polypeptide sample were determined based on peak area .
Figure imgf000016_0001
EXAMPLE 6
Formation of Acetate Salt
The product of any one of Examples 1-3 is contacted with an aqueous solution of acetic acid to form the polypeptide acetate salt .
DISCUSSION
The inventors of the disclosed invention found that hydrogenolysis is effective in removing the benzyl groups from glutamate residues of the protected polypeptides . Specifically, the inventors of the instant invention found that the use of hydrogenolysis using a palladium/carbon catalyst is effective in removing the benzyl groups from glutamate residues to form a trifluoroacetyl polypeptide, which is protected by the trifluoroacetyl groups on the lysine residues . Catalyst, for example palladium/carbon, can be recovered and reused thereby eliminating waste . The trifluoroacetyl groups were subsequently removed from the lysine residues by piperidine .
Other hydrogenolysis catalysts may also be used to remove the benzyl groups from the glutamate residues . Such known hydrogenolysis catalysts are Raney Nickel , Pt , Pt/C, PtO2, Pd (OH) 2 , Bh/C, RhCl (PPh3 J 3 , and other transition metal catalysts . The hydrogenolysis reaction can be performed at a temperature between 200C and 1000C and a pressure between 1 atm and 100 atm.
Using hydrogenolysis instead of HBr/acetic acid to remove the benzyl groups , however, posed a further complication .
When HBr/acetic acid is used, it serves the dual function of both removing the benzyl groups from the glutamate residues and cleaving the polypeptide to achieve a desired average molecular weight of the mixture . Hydrogenolysis , however, does not cleave the polypeptide . Therefore, inventors of the disclosed process further modified the production process to achieve the desired peak molecular weight by using specific amounts of the initiator of the polymerization reaction .
Initiators that can be used are n-hexylamine and other primary amines , diethylamine and other other dialkyl amines , or sodium methoxide or any combination of initiators . U. S . Patent No . 5 , 800 , 808 , issued September 1, 1998 (Konfino, et al . ) discloses the use of 0.1-0.2% diethylamine as an initiator in a process conducted at room temperature for 24 hours that also uses HBr to achieve polypeptides with a molecular weight in the range of 5000-9000 daltons . In contrast, in their examples applicants have used 3.9 g of diethylamine as an initiator with 7.43 g of L-tyrosine N- carboxyanhydride, 34.61 g of N6-trifluoroacetyl-L-Lysine N- carboxyanhydride, 21.25 g of L-alanine N-carboxyanhydride and 14.83 g of 5-benzyl L-glutamate N-carboxyanhydride in a process conducted at 23°C to 27°C for 24 hours to achieve a mixture of polypeptides with a mean molecular weight of 12 , 700 daltons . The peak molecular weight of the mixture of polypeptides is also affected by the process temperature and reaction time .
In any embodiment of the subject invention, determination of the peak molecular weight of the mixture of polypeptides can be conducted after polymerization of the polypeptide but before removal of either the benzyl protecting group or the trifluoroacetyl protecting group . Alternatively, in any embodiment of the subject invention, the peak molecular weight of the mixture of polypeptides may be determined after removal of the benzyl protecting but before removal of the trifluoroacetyl protecting group . Still another alternative in any embodiment of the subject invention is to determine the peak molecular weight of the mixture of polypeptides after removal of both protecting groups from the polypeptide . Adjustment of the peak molecular weight of the mixture of polypeptides can similarly be performed at the mentioned steps of the process by known techniques such as chromatographic fractionation, filtration, ultrafiltration dialysis , enzymatic hydrolysis or sedimentation.
The subject invention provides a process for making a mixture of acetate salts of polypeptides each of which consisting of glutamic acid, alanine, tyrosine and lysine which provides reduced production of aqueous waste and improved control of the peak molecular weight of the mixture of acetate salts of polypeptides .

Claims

What is claimed is :
1. A process for making a mixture of acetate salts of polypeptides , each of which consisting of glutamic acid, alanine, tyrosine and lysine, wherein the mixture has a desired peak molecular weight , comprising : a) polymerizing N-carboxyanhydrides of tyrosine, alanine, γ-benzyl glutamate and trifluoroacetyllysine with an initiator in an amount of 0.01% to 20% by weight for a suitable period of time and at a suitable temperature to form a mixture of protected polypeptides , which mixture of polypeptides in unprotected form having a first peak molecular weight ; b) removing the benzyl protecting group from the mixture of protected polypeptides by contacting the polypeptides with a hydrogenolysis catalyst and hydrogen to produce a mixture of trifluoroacetyl protected polypeptides , which mixture of polypeptides in unprotected form having the first peak molecular weight ; c ) removing the trifluoroacetyl protecting group from the trifluoroacetyl protected polypeptides by contacting the polypeptides with an organic base solution to form a mixture of polypeptides, which mixtures of polypeptides in unprotected form having the first peak molecular weight; d) removing the free trifluoroacetyl groups and low molecular weight impurities by ultrafiltration to obtain the mixture of polypeptides each of which consisting of glutamic acid, alanine, tyrosine and lysine ; and e) contacting the mixture of polypeptides each of which consisting of glutamic acid, alanine, tyrosine and lysine with an aqueous solution of acetic acid to form the mixture of acetate salts of polypeptides each of which consisting of glutamic acid, alanine, tyrosine and lysine and having the desired peak molecular weight .
2. The process of claim 1, wherein the first peak molecular weight is 2 , 000 daltons to 40 , 000 daltons .
3. The process of claim 2 , wherein the first peak molecular weight is 4 , 700 daltons to 11, 000 daltons .
4. The process of claim 2 , wherein the first peak molecular weight is 12 , 500 daltons .
5. The process of claim 1, wherein the desired peak molecular weight is 2 , 000 daltons to 40 , 000 daltons .
6. The process of claim 5 , wherein the desired peak molecular weight is 4 , 700 daltons to 11 , 000 daltons .
7. The process of claim 5 , wherein the desired peak molecular weight is 12 , 500 daltons .
8. The process of claim 1, wherein the hydrogenolysis catalyst is Palladium/carbon, Raney Nickel, Pt, Pt/C, PtO2, Pd(OH) 2 , Rh/C, or RhCl (PPh3J 3 .
9. The process of claim 8 , wherein the hydrogenolysis catalyst is Palladium/carbon.
10. The process of claim 9 , wherein the weight ratio of protected polypeptide to palladium/carbon catalyst is 10 : 1.
11. The process of claim 1, wherein the step of contacting the polypeptides with the hydrogenolysis catalyst is performed in a solvent selected from the group consisting of methanol , ethanol or isopropanol .
12. The process of claim 11, wherein the solvent is methanol .
13. The process of claim 1 , wherein the initiator is a primary amine, a dialkyl amine or sodium methoxide .
14. The process of claim 13 , wherein the initiator is diethylamine .
15. The process of claim 1, wherein the amount of initiator is 1% to 10% by weight .
16. The process of claim 15 , wherein the amount of initiator is 2% to 5% by weight .
17. The process of claim 16 , wherein the amount of initiator is 2% by weight .
18. The process of claim 16 , wherein the amount of initiator is 5% by weight .
19. The process of claim 1, wherein the organic base in step c) is an aqueous organic base .
20. The process of claim 19 , wherein the aqueous organic base is a primary, secondary or tertiary amine or methanolic ammonia.
21. The process of claim 20 , wherein the aqueous organic base is piperidine.
22. A mixture of acetate salts of polypeptides made by the process of any one of claims 1-21.
23. A pharmaceutical composition comprising the mixture of claim 22 and a pharmaceutically acceptable carrier.
24. A process for preparing a pharmaceutical composition comprising mixing the mixture of claim 22 with a pharmaceutically acceptable carrier.
25. In a process for preparing a pharmaceutical composition containing an aqueous mixture of acetate salts of polypeptides each of which consisting of glutamic acid, alanine, tyrosine and lysine, wherein the mixture has a desired peak molecular weight, the improvement comprising making the mixture of acetate salts of polypeptides by the process of any one of claims 1-21.
26. A process for making a mixture of trifluoroacetyl protected polypeptides , each of which consisting of glutamic • acid, alanine, tyrosine and trifluoroacetyllysine, wherein the mixture of polypeptides in unprotected form has a first peak molecular weight, comprising : a) polymerizing N-carboxyanhydrides of tyrosine, alanine, γ-benzyl glutamate and trifluoroacetyllysine with an initiator in an amount of 0.01% to 20% by weight for a suitable period of time and at a suitable temperature to form a mixture of protected polypeptides , which mixture of polypeptides in unprotected form having a first peak molecular weight; and b) removing the benzyl protecting group from the mixture of protected polypeptides by contacting the polypeptides with a hydrogenolysis catalyst and hydrogen, to obtain the mixture of trifluoroacetyl protected polypeptides each of which consisting of glutamic acid, alanine, tyrosine and trifluoroacetyllysine and which mixture of polypeptides in unprotected form having the first peak molecular weight .
27. The process of claim 26 , wherein the hydrogenolysis catalyst is Palladium/carbon, Raney Nickel , Pt, Pt/C, PtO2 , Pd (OH) 2, Rh/C, or RhCl (PPh3) 3.
28. The process of claim 27 , wherein the hydrogenolysis catalyst is Palladium/carbon.
29. The process of claim 28 , wherein the weight ratio of protected polypeptide to palladium/carbon catalyst is 10 : 1.
30. The process of claim 26 , wherein the step of contacting the polypeptides with a hydrogenolysis catalyst is performed in a solvent selected from the group consisting of methanol , ethanol or isopropanol .
31. The process of claim 30 , wherein the solvent is methanol .
32. The process of claim 26 , wherein the initiator is a primary amine, a dialkyl amine or sodium methoxide .
33. The process of claim 32 , wherein the initiator is diethylamine .
34. The process of claim 26 , wherein the amount of initiator is 1% to 10% by weight .
35. The process of claim 34 , wherein the amount of initiator is 2% to 5% by weight .
36. The process of claim 35 , wherein the amount of initiator is 2% by weight .
37. The process of claim 35 , wherein the amount of initiator is 5% by weight .
38. The process of claim 26 , wherein the first peak molecular weight is 2 , 000 daltons to 40 , 000 daltons .
39. The process of claim 38, wherein the first peak molecular weight is 4 , 700 daltons to 11, 000 daltons .
40. The process of claim 39 , wherein the first peak molecular weight is 12 , 500 daltons .
41. A mixture of trifluoroacetyl protected polypeptides each of which consisting of glutamic acid, alanine, tyrosine and trifluoroacetyllysine produced by the process of any one of claims 26-40.
42. A process of making a mixture of acetate salts of polypeptides , each of which consisting of glutamic acid, alanine, tyrosine and lysine, wherein the mixture has a desired peak molecular weight, comprising: a) treating the mixture of claim 41 with an organic base solution, b) removing the free trifluoroacetyl groups and low molecular weight impurities by ultrafiltration to obtain a mixture of polypeptides each of which consisting of glutamic acid, alanine, tyrosine and lysine, and c) contacting the mixture of polypeptides with an aqueous solution of acetic acid to form the mixture of acetate salts of polypeptides , each of which consisting of glutamic acid, alanine, tyrosine and lysine having the desired peak molecular weight .
43. The process of claim 42 , wherein the organic base is an aqueous organic base.
44. The process of claim 43 , wherein the aqueous organic base is a primary, secondary or tertiary amine or methanolic ammonia.
45. The process of claim 44 , wherein the aqueous organic base is piperidine.
PCT/US2006/002351 2005-02-02 2006-01-20 Process for producing polypeptide mixtures using hydrogenolysis Ceased WO2006083608A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AU2006211510A AU2006211510B8 (en) 2005-02-02 2006-01-20 Process for producing polypeptide mixtures using hydrogenolysis
EP06719275A EP1838326A4 (en) 2005-02-02 2006-01-20 Process for producing polypeptide mixtures using hydrogenolysis
NZ556156A NZ556156A (en) 2005-02-02 2006-01-20 Process for producing acetate salts of polypeptides using hydrogenolysis
CA002594022A CA2594022A1 (en) 2005-02-02 2006-01-20 Process for producing polypeptide mixtures using hydrogenolysis
BRPI0606301-2A BRPI0606301A2 (en) 2005-02-02 2006-01-20 process for making a mixture of polypeptide acetate salts, process for making a mixture of unprotected trifluoroacetyl polypeptide salts, mixture of polypeptide acetate salts, pharmaceutical composition, processes for preparing a pharmaceutical composition, and protected trifluoroacetyl polypeptides
MX2007009296A MX2007009296A (en) 2005-02-02 2006-01-20 Process for producing polypeptide mixtures using hydrogenolysis.
JP2007553163A JP2008528589A (en) 2005-02-02 2006-01-20 Method for making polypeptide mixtures using hydrogenolysis
IL183610A IL183610A0 (en) 2005-02-02 2007-05-31 Process for producing polypeptide mixtures using hydrogenolysis
IS8657A IS8657A (en) 2006-01-20 2007-06-29 A method of producing polypeptide preparations using hydrogen peroxide
NO20074374A NO20074374L (en) 2005-02-02 2007-08-28 Process for the preparation of polypeptide mixtures using hydrogenolysis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64944205P 2005-02-02 2005-02-02
US60/649,442 2005-02-02

Publications (1)

Publication Number Publication Date
WO2006083608A1 true WO2006083608A1 (en) 2006-08-10

Family

ID=36777558

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/002351 Ceased WO2006083608A1 (en) 2005-02-02 2006-01-20 Process for producing polypeptide mixtures using hydrogenolysis

Country Status (16)

Country Link
US (1) US20060172942A1 (en)
EP (1) EP1838326A4 (en)
JP (1) JP2008528589A (en)
KR (1) KR20070108388A (en)
CN (1) CN101111252A (en)
AU (1) AU2006211510B8 (en)
BR (1) BRPI0606301A2 (en)
CA (1) CA2594022A1 (en)
IL (1) IL183610A0 (en)
MX (1) MX2007009296A (en)
NO (1) NO20074374L (en)
NZ (1) NZ556156A (en)
RU (1) RU2419638C2 (en)
UA (1) UA93669C2 (en)
WO (1) WO2006083608A1 (en)
ZA (1) ZA200705874B (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010072418A1 (en) 2008-12-24 2010-07-01 Synthon Bv A process for purifying a polymer mixture
US7884187B2 (en) 2008-04-16 2011-02-08 Momenta Pharmaceuticals, Inc. Analysis of amino acid copolymer compositions
US8324348B1 (en) 2011-07-11 2012-12-04 Momenta Pharmaceuticals, Inc. Evaluation of copolymer diethylamide
US8575198B1 (en) 2011-09-07 2013-11-05 Momenta Pharmaceuticals, Inc. In-process control for the manufacture of glatiramer acetate
US8709433B2 (en) 2010-10-11 2014-04-29 Teva Pharmaceutical Industries Ltd. Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
US8815511B2 (en) 2011-10-10 2014-08-26 Teva Pharmaceutical Industries, Ltd. Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate
WO2014060942A3 (en) * 2012-10-20 2014-10-23 Mahesh Kandula Compositions and methods of for the treatment of multiple sclerosis and neurodegenerative diseases
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
US9155776B2 (en) 2009-08-20 2015-10-13 Yeda Research & Development Co., Ltd. Low frequency glatiramer acetate therapy
US9617596B2 (en) 2012-10-10 2017-04-11 Teva Pharmaceutical Industries, Ltd. Biomarkers predictive for clinical response for glatiramer acetate
US9702007B2 (en) 2013-10-21 2017-07-11 Teva Pharmaceuticals Industries, Ltd. Genetic markers predictive of response to glatiramer acetate
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
US12370233B2 (en) 2016-08-31 2025-07-29 Mapi Pharma Ltd. Depot systems comprising glatiramer acetate

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (en) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Treatment of Crohn's disease with copolymer 1 and polypeptides
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US7429374B2 (en) * 2001-12-04 2008-09-30 Teva Pharmaceutical Industries, Ltd. Process for the measurement of the potency of glatiramer acetate
EP1778286A4 (en) * 2004-03-03 2009-04-08 Teva Pharma Combination therapy with glatiramer acetate and riluzole
HRP20160455T1 (en) * 2004-09-09 2016-07-15 Yeda Research And Development Co., Ltd. Mixtures of polypeptides, their compositions and methods for their preparation, and their uses
ZA200702591B (en) * 2004-09-09 2009-03-25 Teva Pharma Process for preparation of mixtures of polypeptides using purified hydrobromic acid
US8324641B2 (en) * 2007-06-29 2012-12-04 Ledengin, Inc. Matrix material including an embedded dispersion of beads for a light-emitting device
WO2006089164A1 (en) * 2005-02-17 2006-08-24 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
CA2606194A1 (en) * 2005-04-25 2006-11-02 Yeda Research And Development Company Markers associated with the therapeutic efficacy of glatiramer acetate
US8993722B2 (en) * 2007-07-31 2015-03-31 Natco Pharma Limited Process for the preparation glatiramer acetate (copolymer-1)
WO2009017775A2 (en) * 2007-08-02 2009-02-05 Scinopharm Taiwan Ltd. Process for the preparation of a polypeptide
CA2702437C (en) * 2007-11-28 2013-06-25 Teva Pharmaceutical Industries Ltd. Method of delaying the onset of clinically definite multiple sclerosis
KR20110059606A (en) * 2008-08-07 2011-06-02 시노팜 타이완 리미티드 Synthesis of Glatiramer Acetate
RU2011144566A (en) 2009-04-03 2013-05-10 Момента Фармасьютикалз, Инк. CONTROL OF COPOLYMER COMPOSITIONS
US9109006B2 (en) * 2010-07-29 2015-08-18 Santhanakrishnan Srinivasan Glatiramer acetate molecular weight markers
CA2827275A1 (en) 2011-02-14 2012-09-20 Usv Limited Copolymer-1, process for preparation and analytical methods thereof
GB2478837A (en) * 2011-03-14 2011-09-21 Cipla Ltd Preparation of glatiramer
CN103265624B (en) * 2013-05-27 2015-04-22 成都圣诺生物制药有限公司 Method for preparing copaxone
CN104610436A (en) * 2015-02-03 2015-05-13 郑州大明药物科技有限公司 Preparation method of glatiramer acetate

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3849550A (en) * 1971-04-21 1974-11-19 Yeda Res & Dev Therapeutic copolymer
US6048898A (en) * 1994-05-24 2000-04-11 Yeda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
WO2004043995A2 (en) * 2002-11-13 2004-05-27 Apotex Pharmachem Inc. Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3846550A (en) * 1971-01-21 1974-11-05 H Akrongold Cosmetic skin powder containing urea
JPS5828867B2 (en) * 1979-07-13 1983-06-18 財団法人 微生物化学研埋会 New tetrapeptide derivatives
US4935405A (en) * 1986-10-31 1990-06-19 Pfizer Inc. Nor-statine and nor-cyclostatine polypeptides
MX9301789A (en) * 1992-04-03 1993-10-01 Iaf Biochem Int NEW LIPOPHILIC OLIGOPEPTIDES WITH IMMUNOMODULATING ACTIVITY.
RU2198900C2 (en) * 1994-05-24 2003-02-20 Еда Рисерч энд Дивелопмент Ко., Лтд. Improved copolymer-1 and method of preparation thereof
JP3622187B2 (en) * 1995-09-26 2005-02-23 Jsr株式会社 Method for producing poly-α-amino acid particles
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
ES2527760T3 (en) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Treatment of Crohn's disease with copolymer 1 and polypeptides
IL141021A0 (en) * 1998-07-23 2002-02-10 Yeda Res & Dev Treatment of autoimmune conditions with copolymer 1 and related copolymers
US6800287B2 (en) * 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6514938B1 (en) * 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6872739B1 (en) * 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
JP4328050B2 (en) * 2000-01-20 2009-09-09 イエダ リサーチ アンド デベロップメント カンパニー リミテッド Use of Copolymer 1, related peptides and polypeptides and T cells treated with them for neuroprotective therapy
US7022663B2 (en) * 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
US20020077278A1 (en) * 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en) * 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
US7429374B2 (en) * 2001-12-04 2008-09-30 Teva Pharmaceutical Industries, Ltd. Process for the measurement of the potency of glatiramer acetate
UA78854C2 (en) * 2002-09-06 2007-04-25 Kissei Pharmaceutical Crystal for an oral solid drug and oral solid drug for dysuria treatment containing the same
CA2411786C (en) * 2002-11-13 2009-01-27 Brantford Chemicals Inc. A process for the preparation of polypeptides from n-carboxyanhydrides of amino acids
RU2339397C2 (en) * 2003-01-21 2008-11-27 Йеда Рисерч Энд Дивелопмент Ко.Лтд. Cop1 for treatment of inflammatory diseases of intestine
US20070037740A1 (en) * 2003-03-04 2007-02-15 Irit Pinchasi Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
WO2004103297A2 (en) * 2003-05-14 2004-12-02 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
JP2007509981A (en) * 2003-10-31 2007-04-19 テバ ファーマシューティカル インダストリーズ リミティド Nanoparticles for drug delivery
WO2005048435A1 (en) * 2003-11-13 2005-05-26 Sew-Eurodrive Gmbh & Co. Kg Compact drive
EP1778286A4 (en) * 2004-03-03 2009-04-08 Teva Pharma Combination therapy with glatiramer acetate and riluzole
US20070237717A1 (en) * 2004-04-05 2007-10-11 Roland Martin Methods for Selection of Subjects for Multiple Sclerosis Therapy
HRP20160455T1 (en) * 2004-09-09 2016-07-15 Yeda Research And Development Co., Ltd. Mixtures of polypeptides, their compositions and methods for their preparation, and their uses
ZA200702591B (en) * 2004-09-09 2009-03-25 Teva Pharma Process for preparation of mixtures of polypeptides using purified hydrobromic acid
US20100167983A1 (en) * 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
CA2901244A1 (en) * 2005-02-23 2006-08-31 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
CA2606194A1 (en) * 2005-04-25 2006-11-02 Yeda Research And Development Company Markers associated with the therapeutic efficacy of glatiramer acetate
US20070059798A1 (en) * 2005-09-09 2007-03-15 Alexander Gad Polypeptides useful for molecular weight determinations
EP1954667B1 (en) * 2005-11-17 2017-02-08 Teva Pharmaceutical Industries Ltd Methods for isolating propargylated aminoindans
WO2007081975A2 (en) * 2006-01-11 2007-07-19 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
CA2702437C (en) * 2007-11-28 2013-06-25 Teva Pharmaceutical Industries Ltd. Method of delaying the onset of clinically definite multiple sclerosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3849550A (en) * 1971-04-21 1974-11-19 Yeda Res & Dev Therapeutic copolymer
US6048898A (en) * 1994-05-24 2000-04-11 Yeda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
WO2004043995A2 (en) * 2002-11-13 2004-05-27 Apotex Pharmachem Inc. Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ITOH M.: "Selective Protection of alpha or Side-chain Carboxyl Groups of Aspartic and Glutamic Acid. A Facile Synthesis of beta-Aspartyl and gamma-Glutamyl", PEPTIDES, vol. 17, no. 8, 1969, pages 1679 - 1686, XP008070902 *
See also references of EP1838326A4 *

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10160992B2 (en) 2008-04-16 2018-12-25 Momenta Pharmaceuticals, Inc. Analysis of amino acid copolymer compositions
US9085796B2 (en) 2008-04-16 2015-07-21 Momenta Pharmaceuticals, Inc. Analysis of amino acid copolymer compositions
US8329391B2 (en) 2008-04-16 2012-12-11 Momenta Pharmaceuticals, Inc. Analysis of amino acid copolymer compositions
US9395374B2 (en) 2008-04-16 2016-07-19 Momenta Pharmaceuticals, Inc. Analysis of amino acid copolymer compositions
US8592142B2 (en) 2008-04-16 2013-11-26 Momenta Pharmaceuticals, Inc. Analysis of amino acid copolymer compositions
US7884187B2 (en) 2008-04-16 2011-02-08 Momenta Pharmaceuticals, Inc. Analysis of amino acid copolymer compositions
US9410964B2 (en) 2008-04-16 2016-08-09 Momenta Pharmaceuticals, Inc. Analysis of amino acid copolymer compositions
US9617313B2 (en) 2008-12-24 2017-04-11 Synthon Bv Process for purifying a polymer mixture
WO2010072418A1 (en) 2008-12-24 2010-07-01 Synthon Bv A process for purifying a polymer mixture
EP2796463A1 (en) 2008-12-24 2014-10-29 Synhton B.V. A process for purifying a polymer mixture
US9402874B2 (en) 2009-08-20 2016-08-02 Yeda Research & Development Co., Ltd. Low frequency glatiramer acetate therapy
US9155776B2 (en) 2009-08-20 2015-10-13 Yeda Research & Development Co., Ltd. Low frequency glatiramer acetate therapy
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
USRE50301E1 (en) 2010-01-04 2025-02-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
US9687522B2 (en) 2010-03-16 2017-06-27 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
US8709433B2 (en) 2010-10-11 2014-04-29 Teva Pharmaceutical Industries Ltd. Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate
US9625473B2 (en) 2010-10-11 2017-04-18 Teva Pharmaceutical Industries Ltd. Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
US9063153B2 (en) 2010-10-11 2015-06-23 Teva Pharmaceuticals Industries Ltd. Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
US8324348B1 (en) 2011-07-11 2012-12-04 Momenta Pharmaceuticals, Inc. Evaluation of copolymer diethylamide
US8765911B2 (en) 2011-07-11 2014-07-01 Momenta Pharmaceuticals, Inc. Evaluation of copolymer diethylamide
US8759484B2 (en) 2011-07-11 2014-06-24 Momenta Pharmaceuticals, Inc. Evaluation of copolymer diethylamide
US8575198B1 (en) 2011-09-07 2013-11-05 Momenta Pharmaceuticals, Inc. In-process control for the manufacture of glatiramer acetate
US9499868B2 (en) 2011-10-10 2016-11-22 Teva Pharmaceutical Industries, Ltd. Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate
US8815511B2 (en) 2011-10-10 2014-08-26 Teva Pharmaceutical Industries, Ltd. Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate
US9617596B2 (en) 2012-10-10 2017-04-11 Teva Pharmaceutical Industries, Ltd. Biomarkers predictive for clinical response for glatiramer acetate
WO2014060942A3 (en) * 2012-10-20 2014-10-23 Mahesh Kandula Compositions and methods of for the treatment of multiple sclerosis and neurodegenerative diseases
US9702007B2 (en) 2013-10-21 2017-07-11 Teva Pharmaceuticals Industries, Ltd. Genetic markers predictive of response to glatiramer acetate
US9763993B2 (en) 2015-01-28 2017-09-19 Teva Pharmaceutical Industries Ltd. Process for manufacturing glatiramer acetate product
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
US12370233B2 (en) 2016-08-31 2025-07-29 Mapi Pharma Ltd. Depot systems comprising glatiramer acetate
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems
US12343371B2 (en) 2017-03-26 2025-07-01 Mapi Pharma Ltd. Method for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using a sustained release depot formulation comprising glatiramer acetate

Also Published As

Publication number Publication date
UA93669C2 (en) 2011-03-10
CN101111252A (en) 2008-01-23
IL183610A0 (en) 2008-04-13
RU2419638C2 (en) 2011-05-27
BRPI0606301A2 (en) 2009-07-07
NO20074374L (en) 2007-10-24
KR20070108388A (en) 2007-11-09
EP1838326A1 (en) 2007-10-03
AU2006211510B8 (en) 2011-04-21
RU2007132889A (en) 2009-03-10
NZ556156A (en) 2010-03-26
US20060172942A1 (en) 2006-08-03
MX2007009296A (en) 2007-09-21
CA2594022A1 (en) 2006-08-10
AU2006211510A1 (en) 2006-08-10
EP1838326A4 (en) 2009-09-30
ZA200705874B (en) 2009-04-29
JP2008528589A (en) 2008-07-31
AU2006211510B2 (en) 2011-03-10

Similar Documents

Publication Publication Date Title
EP1838326A1 (en) Process for producing polypeptide mixtures using hydrogenolysis
US8536305B2 (en) Processes for preparing a polypeptide
EP2675824B1 (en) Copolymer-1, process for preparation and analytical methods thereof
US8212002B2 (en) Synthesis of glatiramer acetate
EP2414384B2 (en) Control of copolymer compositions
US7049399B2 (en) Process for the preparation of polypeptide 1
EP1565486A2 (en) Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine
WO2011139752A2 (en) Preparation of polypeptides and salts thereof
CA2767919C (en) Processes for preparing glatiramer
JPS6330499A (en) Opioid peptide-polypeptide complex

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680003522.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 183610

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2594022

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 556156

Country of ref document: NZ

Ref document number: 2006211510

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007553163

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 5370/DELNP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2006211510

Country of ref document: AU

Date of ref document: 20060120

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2006719275

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/009296

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020077019848

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2007132889

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0606301

Country of ref document: BR

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 207328

Country of ref document: IL